Drugs / APC101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07599800 | Aug 2026 → Dec 2028 expected | postherpetic neuralgia | Andros Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APC101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07599800 ↗ |